43 Pharmas Apply To Make Generics Of Off-Patent Plavix In China

China’s State FDA received applications from 43 Chinese drug companies to manufacture generics of Sanofi’s $10-billion anti-clotting drug Plavix, whose patent expired in May.

China’s State FDA received applications from 43 Chinese drug companies to manufacture generics of Sanofi’s $10-billion anti-clotting drugPlavix (clopidogrel), whose patent expired in May. Fifteen companies have gained approvals, including nine API makers (including Shenzhen Salubris Pharmaceutical Co., Ltd.) and two formulation producers (including Henan XInShuaike Pharmaceutical Co., Ltd.). According to SFDA figures, Plavix sales growth subdued from 65.7% in 2007 to 22% in 2011, and sales will likely reach RMB 20 billion in 2015, from RMB 6.8 billion in 2010. Looking forward, the drug will face competition from the increasingly prominent Taijia (clopidogrel) manufactured by Shenzhen Salubris, whose market share grew from 9.2% to 26.69% during 2006-2011, and other upcoming generics. (Click Here For More - Chinese Language

)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

China’s Mid-Cap Companies Thriving On Big Pharma Deals

 

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.

More from Focus On Asia

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

Asia Deal Watch: JCR And Alexion Build Upon Existing Gene Therapy Alliances

Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.